Bellevue Group’s BridgeBio Pharma BBIO Stock Holding History

Bellevue Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.6M	Buy	1,189,506 +1,164,129	+4,587%	+$81.5M	1.86%	17
2026 Q1	$1.88M	Buy	25,377 +1,266	+5%	+$91.8K	0.04%	79
2025 Q4	$1.84M	Buy	24,111 +3,755	+18%	+$246K	0.03%	98
2025 Q3	$1.06M	Buy	20,356 +9,956	+96%	+$486K	0.02%	106
2025 Q2	$449K	Hold	10,400	–	–	0.01%	108
2025 Q1	$360K	Hold	10,400	–	–	0.01%	124
2024 Q4	$285K	Hold	10,400	–	–	0.01%	137
2024 Q3	$265K	Sell	10,400 -2,400	-19%	-$63K	﹤0.01%	141
2024 Q2	$324K	Hold	12,800	–	–	0.01%	137
2024 Q1	$396K	Sell	12,800 -20,500	-62%	-$697K	0.01%	138
2023 Q4	$1.34M	Sell	33,300 -45,400	-58%	-$1.36M	0.02%	116
2023 Q3	$2.08M	Sell	78,700 -18,200	-19%	-$516K	0.03%	113
2023 Q2	$1.67M	Buy	96,900 +14,300	+17%	+$215K	0.02%	118
2023 Q1	$1.37M	Buy	+82,600	New	+$963K	0.02%	122

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bellevue Group's BBIO Position: Q2 2026 in Review

Bellevue Group increased its BridgeBio Pharma (BBIO) stake by 4,587% in Q2 2026, buying an estimated $81.5M and bringing the position to 1,189,506 shares worth $88.6M. The position accounts for 1.86% of the portfolio, ranked #17.

Bellevue Group first reported a position in BBIO in Q1 2023 and has held it in 14 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Bellevue Group held 1,189,506 shares of BridgeBio Pharma worth $88.6M as of Q2 2026.
Bellevue Group bought 1,164,129 BridgeBio Pharma shares in Q2 2026, an estimated $81.5M.
BridgeBio Pharma made up 1.86% of Bellevue Group's portfolio in Q2 2026, its #17 holding.
Bellevue Group first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 14 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.